**Alsenz 2007** Alsenz, J., Meister, E. & Haenel, E. Development of a partially automated solubility screening (PASS) assay for early drug development. J. Pharm. Sci. 96, 1748–62 (2007).

**Atkinson 1988** Atkinson, H.C. & Begg, E.J. Relationship between human milk lipid-ultrafiltrate and octanolwater partition coefficients. J. Pharm. Sci. 77, 796–8 (1988).

**Bauer 2008** Bauer, L.A. Applied Clinical Pharmacokinetics. (2008).

**Becquemont 2001** Becquemont, L. et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70, 311–6 (2001). 

**Caldwell 1976** Caldwell, J.H. & Cline, C.T. Biliary excretion of digoxin in man. Clin. Pharmacol. Ther. 19, 410–5 (1976).

**Collett 2004** Collett, A., Tanianis-Hughes, J., Hallifax, D. & Warhurst, G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wildtype and mdr1a(-/-) mice in vivo. Pharm. Res. 21, 819–26 (2004).

**Ding 2004** Ding, R. et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73–84 (2004). 

**Drugbank.ca** (https://go.drugbank.com/drugs/DB00390)

**Eckermann 2012** Eckermann, G., Lahu, G., Nassr, N. & Bethke, T.D. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. J. Clin. Pharmacol. 52, 251–7 (2012).

**Friedrich 2011** Friedrich, C. et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. 36, 17–24 (2011). 

**Greiner 1999** Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147–53 (1999).

**Gurley 2008** Gurley, B.J., Swain, A., Williams, D.K., Barone, G. & Battu, S.K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. food Res. 52, 772–9 (2008). 

**Hanke 2018** Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics Syst Pharmacol.. 2018 Oct;7(10):647-659.

**Hayward 1978** Hayward, R.P., Greenwood, H. & Hamer, J. Comparison of digoxin and medigoxin in normal subjects. Br. J. Clin. Pharmacol. 6, 81–6 (1978). 

**Hinderling 1984** Hinderling, P.H. Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. J. Pharm. Sci. 73, 1042–53 (1984).

**Jalava 1997** Jalava, K.M., Partanen, J. & Neuvonen, P.J. Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. 19, 609–13 (1997). 

**Johne 1999** Johne, A. et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66, 338–45 (1999). 

**Katz 2010** Katz, A. et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J. Biol. Chem. 285, 19582–92 (2010).

**Kirch 1986** Kirch, W., Hutt, H.J., Dylewicz, P., Gräf, K.J. & Ohnhaus, E.E. Dose-dependence of the nifedipine-digoxin interaction? Clin. Pharmacol. Ther. 39, 35–9 (1986). 

**Koup 1975** Koup, J.R., Greenblatt, D.J., Jusko, W.J., Smith, T.W. & Koch-Weser, J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J. Pharmacokinet. Biopharm. 3, 181–92 (1975). 

**Kramer 1979** Kramer, W.G. et al. Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7, 47–61 (1979). 

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19.

**Lalonde 1985** Lalonde, R.L., Deshpande, R., Hamilton, P.P., McLean, W.M. & Greenway, D.C. Acceleration of digoxin clearance by activated charcoal. Clin. Pharmacol. Ther. 37, 367–71 (1985). 

**Larsen 2007** Larsen, U.L. et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand. J. Clin. Lab. Invest. 67, 123–34 (2007).

**Martin 1997** Martin, D.E. et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br. J. Clin. Pharmacol. 43, 661–4 (1997). 

**Neuhoff 2013** Neuhoff, S. et al. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J. Pharm. Sci. 102, 3145–60 (2013).

**Nishimura 2005** Nishimura, M. & Naito, S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet. 20, 452–77 (2005).

**Obach 2008** Obach, R.S., Lombardo, F. & Waters, N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36, 1385–405 (2008).

**Ochs 1975** Ochs, H., Bodem, G., Schäfer, P.K., Kodrat, G., Dengler, H.J. Absorption of digoxin from the distal parts of the intestine in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):95-7.

**Ochs 1978** Ochs, H.R., Greenblatt, D.J., Bodem, G. & Harmatz, J.S. Dose-independent pharmacokinetics of digoxin in humans. Am. Heart J. 96, 507–11 (1978). 

**Oosterhuis 1991** Oosterhuis, B., Jonkman, J.H., Andersson, T., Zuiderwijk, P.B. & Jedema, J.N. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br. J. Clin. Pharmacol. 32, 569–72 (1991). 

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Prasad 2014** Prasad, B. et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab. Dispos. 42, 78–88 (2014).

**Qiu 2010** Qiu, R. et al. Lack of a pharmacokinetic interaction between dimebon (latrepirdine) and digoxin in healthy subjects. Am. Soc. Clin. Pharmacol. Ther. Meet. Atlanta, GA, USA (2010). 

**Ragueneau 1999** Ragueneau, I. et al. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br. J. Clin. Pharmacol. 48, 453–6 (1999). 

**Rengelshausen 2003** Rengelshausen, J. et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. 56, 32–8 (2003).

**Rodin 1988** Rodin, S.M., Johnson, B.F., Wilson, J., Ritchie, P. & Johnson, J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin. Pharmacol. Ther. 43, 668–72 (1988). 

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589.

**Steiness 1982** Steiness, E., Waldorff, S. & Hansen, P.B. Renal digoxin clearance: dependence on plasma digoxin and diuresis. Eur. J. Clin. Pharmacol. 23, 151–4 (1982). 

**Stephens 2001** Stephens R.H., O'Neill C.A., Warhurst A., Carlson G.L., Rowland M-, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol Exp Ther. 2001 Feb;296(2):584-91.

**Tayrouz 2003** Tayrouz, Y. et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin. Pharmacol. Ther. 73, 397–405 (2003). 

**Troutman 2003** Troutman, M.D. & Thakker, D.R. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20, 1200–9 (2003).

**Tsutsumi 2002** Tsutsumi, K. et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1159–64 (2002). 

**Vaidyanathan 2008** Vaidyanathan, S. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 48, 1323–38 (2008). 

**Verstuyft 2003** Verstuyft, C. et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73, 51–60 (2003). 

**Wagner 1981** Wagner, J.G., Popat, K.D., Das, S.K., Sakmar, E. & Movahhed, H. Evidence of nonlinearity in digoxin pharmacokinetics. J. Pharmacokinet. Biopharm. 9, 147–66 (1981). 

**Westphal 2000** Westphal, K. et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68, 6–12 (2000).